Literature DB >> 9593447

Screening for cervical cancer.

J Cuzick, C J Meijer, J M Walboomers.   

Abstract

Entities:  

Mesh：

Year:  1998        PMID： 9593447     DOI： 10.1016/S0140-6736(05)79490-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  Novel method for detection, typing, and quantification of human papillomaviruses in clinical samples.

Authors:  K W Hart; O M Williams; N Thelwell; A N Fiander; T Brown; L K Borysiewicz; C M Gelder
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

2.  Th2 type inflammation promotes the gradual progression of HPV-infected cervical cells to cervical carcinoma.

Authors:  Qinghua Feng; Huafeng Wei; Janice Morihara; Joshua Stern; Mujun Yu; Nancy Kiviat; Ingegerd Hellstrom; Karl Erik Hellstrom
Journal:  Gynecol Oncol       Date:  2012-07-22       Impact factor: 5.482

3.  Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine.

Authors:  Ricardo Rosales; Mario López-Contreras; Carlos Rosales; Jose-Roberto Magallanes-Molina; Roberto Gonzalez-Vergara; Jose Martin Arroyo-Cazarez; Antonio Ricardez-Arenas; Armando Del Follo-Valencia; Santiago Padilla-Arriaga; Miriam Veronica Guerrero; Miguel Angel Pirez; Claudia Arellano-Fiore; Freddy Villarreal
Journal:  Hum Gene Ther       Date:  2014-12       Impact factor: 5.695

Review 4.  Immune therapy for human papillomaviruses-related cancers.

Authors:  Ricardo Rosales; Carlos Rosales
Journal:  World J Clin Oncol       Date:  2014-12-10

5.  HPV testing for cervical cancer screening appears more cost-effective than Papanicolau cytology in Mexico.

Authors:  Yvonne N Flores; David M Bishai; Attila Lorincz; Keerti V Shah; Eduardo Lazcano-Ponce; Mauricio Hernández; Víctor Granados-García; Ruth Pérez; Jorge Salmerón
Journal:  Cancer Causes Control       Date:  2010-12-18       Impact factor: 2.506
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.